Pharmacokinetics of Tacrolimus in Children

Shandong University28 enrolled

Overview

the present study was conducted to assess the population pharmacokinetics of tacrolimus in children with nephrotic syndrome and to use these data to calculate an optimal dosing regimen of tacrolimus for use in these patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nephrotic Syndrome

Interventions

TacrolimusDRUG

Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.

Eligibility

Sex: ALLMin age: 1 MonthMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients have been diagnosed with nephrotic syndrome; * age range: 1 month to 18 years old * tacrolimus used as part of regular treatment Exclusion Criteria: * expected survival time less than the treatment cycle; * patients with other factors that researcher considers unsuitable for inclusion.

Outcomes

Primary Outcomes

change of plasma concentration of Tacrolimus

To detect the plasma concentrations of Tacrolimus after oral administration

Time frame: at 1,2,3,6,9,12 hours after oral administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.